Biotech in Review: Positive Consolidation in China Life Science Companies [View article]
Although SciGen does not currently market products in China, SciGen and Hefei Life Science & Technology Investments established a China joint venture in December 2005. The JV is building a $30 million manufacturing facility for Sci-B-Vac, SciGen’s hepatitis B vaccine. BOTTOM LINE, THEY ARE STILL BUILDING A FACILITY SINCE 2005. ORA-LYN IN PHASE 3, WHAT'S THIS MEAN FOR SHAREHOLDERS? OPPORTUNITY TO GET OUT ON NEWS IF THE STOCK GOES UP. REALITY IS GNBT WON'T BECOME A STAR OVERNIGHT OR GO IN THE BLACK. IT ONLY MAKES SHAREHOLDERS BECOME MORE HYPED ON THE COMPANY BUT DO NOT MAKE THEM RICHER BY NO MEANS!
Biotech in Review: Positive Consolidation in China Life Science Companies [View article]
BOTTOM LINE, THEY ARE STILL BUILDING A FACILITY SINCE 2005. ORA-LYN IN PHASE 3,
WHAT'S THIS MEAN FOR SHAREHOLDERS?
OPPORTUNITY TO GET OUT ON NEWS IF THE STOCK GOES UP.
REALITY IS GNBT WON'T BECOME A STAR OVERNIGHT OR GO IN THE BLACK.
IT ONLY MAKES SHAREHOLDERS BECOME MORE HYPED ON THE COMPANY BUT DO NOT MAKE THEM RICHER BY NO MEANS!